drug design – mycolab.ai

Synthesis and bioactivity of psilocybin analogues containing a stable carbon–phosphorus bond

mycolabadmin

Researchers created new chemical versions of psilocybin (the active compound in magic mushrooms) that cannot be broken down by the body’s natural enzymes in the same way. They tested these new compounds to see if they could help with depression and anxiety by targeting specific brain receptors. The best compound worked well on the intended brain receptors but importantly showed less activity on a heart-related receptor, potentially making it safer than natural psilocybin.

Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential

mycolabadmin

Scientists discovered that psychedelic drugs work by activating a specific signaling pathway in the brain called the 5-HT2A-Gq pathway. By creating new drug-like molecules, they found that drugs need to strongly activate this particular pathway to produce psychedelic effects like hallucinations. This discovery could help researchers design new psychiatric medicines that have therapeutic benefits without the hallucinogenic side effects that worry doctors and patients.

Synthesis and biological assessment of novel 4H-chromene-3-carbonitrile derivatives as tyrosinase inhibitors

mycolabadmin

Researchers developed new chemical compounds that can block tyrosinase, an enzyme responsible for producing excessive skin pigment that causes dark spots and discoloration. The most effective compound (6f) works better than kojic acid, a commonly used skin-lightening ingredient, and could lead to safer treatments for hyperpigmentation and related skin conditions. Computer simulations showed that one form of the compound fits better into the enzyme’s active site, making it more effective at preventing melanin production.

Biological and Cheminformatics Studies of Newly Designed Triazole Based Derivatives as Potent Inhibitors against Mushroom Tyrosinase

mycolabadmin

Researchers developed new chemical compounds based on triazole structures to inhibit tyrosinase, an enzyme that produces melanin in skin. One compound (9h) proved particularly effective at blocking this enzyme, working 170 times better than the standard drug kojic acid. Computer modeling showed how this compound fits into the enzyme’s active site. These findings could lead to safer and more effective treatments for skin discoloration disorders like melasma and age spots.

Identification of (Z)-2-benzylidene-dihydroimidazothiazolone derivatives as tyrosinase inhibitors: Anti-melanogenic effects and in silico studies

mycolabadmin

Scientists developed new chemical compounds that can block tyrosinase, an enzyme that produces skin pigment (melanin). These new compounds, called DHIT derivatives, work much better than existing skin lightening agents like kojic acid and appear to be safer. The best compound tested was 100 times more effective at stopping melanin production than kojic acid in laboratory tests and showed no toxicity to cells.

Research Topic: drug design

Synthesis and bioactivity of psilocybin analogues containing a stable carbon–phosphorus bond

Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential

Synthesis and biological assessment of novel 4H-chromene-3-carbonitrile derivatives as tyrosinase inhibitors

Biological and Cheminformatics Studies of Newly Designed Triazole Based Derivatives as Potent Inhibitors against Mushroom Tyrosinase

Identification of (Z)-2-benzylidene-dihydroimidazothiazolone derivatives as tyrosinase inhibitors: Anti-melanogenic effects and in silico studies